Acadia Healthcare Company, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Acadia Healthcare Company, Inc. on January 21, 2021, covering events occurring on January 19, 2021. The filing primarily addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes and Executive Compensation
On January 19, 2021, the Company entered into a new employment agreement with Ms. Debra K. Osteen, Chief Executive Officer and Board member. Key terms include:
- Annual Cash Compensation: Base salary of $1,000,000 with a target annual bonus of 100% of base salary (maximum 200%).
- Annual Equity Awards: A 2021 long-term incentive award consisting of performance restricted stock units with a target value of $5.2 million. The performance period ends December 31, 2021.
- Termination Payments: In the event of termination without "cause" or resignation for "good reason," Ms. Osteen is entitled to accrued salary and bonuses, continued base salary through December 31, 2021, a full annual bonus (non-prorated), 18 months of health insurance premiums, and accelerated vesting of the long-term incentive award based on performance conditions.
- Restrictive Covenants: Includes non-competition, non-solicitation, and non-disparagement clauses.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies related to financial performance are disclosed in this report, other than the standard contractual obligations associated with the executive agreement.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as Exhibit 10.1 for detailed definitions of "cause" and "good reason."
- Confirm the specific performance metrics tied to the $5.2 million restricted stock unit award.
- Review the Company's most recent 10-K or 10-Q for current financial performance metrics, as this 8-K does not contain them.